Citius Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CTXR Nasdaq 2834 citiuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Jan 8th, 2025 1:00 pm
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - Jan 7th, 2025 1:08 pm
Citius Oncology to explore strategic alternatives - Jan 7th, 2025 12:57 pm
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - Jan 6th, 2025 12:50 pm
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Dec 31st, 2024 12:10 pm
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Dec 30th, 2024 2:43 pm
Citius Pharma Reports 2024 Financial Results and Business Update - Dec 30th, 2024 3:50 am
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Dec 27th, 2024 10:00 pm
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Dec 27th, 2024 2:23 pm
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - Nov 25th, 2024 1:03 pm
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - Nov 22nd, 2024 2:00 pm
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - Nov 18th, 2024 9:05 pm
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - Nov 15th, 2024 6:30 pm
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - Nov 11th, 2024 1:45 pm
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 8:30 pm
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Sep 5th, 2024 12:30 pm
Sidoti Events, LLC's Virtual August Micro-Cap Conference - Aug 13th, 2024 1:30 pm
Citius merges oncology subsidiary with TenX Keane - Aug 13th, 2024 8:32 am
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - Aug 12th, 2024 9:28 pm
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Aug 12th, 2024 8:22 pm